<DOC>
	<DOCNO>NCT02318667</DOCNO>
	<brief_summary>The purpose study evaluate serum soluble human Suppression Tumorigenicity 2 ( ST2 ) protein , receptor IL-33 member proinflammatory IL-1 receptor superfamily , surrogate biological marker predictive disease outcome therapeutic response golimumab treatment subject moderate severe UC fail prior conventional therapy . The primary endpoint study correlate serum soluble ST2 level endoscopic activity ( endoscopic subscore Mayo score ) histological activity ( Geboes index ) disease .</brief_summary>
	<brief_title>Correlation Soluble ST2 With Golimumab ( MK-8259 ) Response Participants With Ulcerative Colitis ( UC ) ( MK-8529-022 ) .</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inadequate response conventional therapy include corticosteroid intolerant , medical contraindication conventional therapy UC diagnose prior screen , base biopsy collect endoscopy Moderate severe active UC total Mayo score 6 12 , inclusive baseline , endoscopic Mayo subscore , great equal 2 Adenomatous polyp remove within last 5 year screen visit prior first drug treatment Extensive colitis ≥ 8 year , disease limit left side colon ≥10 year colonoscopy exclude presence dysplasia within 1 year prior study inclusion colonoscopy exclude presence malignancy screen visit No history untreated latent active Tuberculosis ( TB ) prior screen Negative stool result enteric pathogens History asthma History autoimmune diseases History hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>